GlassScriptPhysician profile
Chante Aksut
NPI 1942696232
$2,896.70
in general payments reported to CMS, 2019-2025
22 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.91 · 2021: $664 · 2022: $888 · 2023: $394 · 2024: $659 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.76 | 2021-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $665.03 | 2022-2025 | |
| Genzyme Corporation | $382.07 | 2020-2024 | |
| Janssen Biotech, INC. | $195.00 | 2021-2023 | Simponi Aria, Stelara, Simponi |
| Leo Pharma INC. | $160.09 | 2021-2025 | Adbry |
| Lilly USA, LLC | $141.79 | 2021-2023 | Olumiant, Taltz |
| Ucb, INC. | $112.56 | 2021-2024 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $107.94 | 2021-2023 | Winlevi |
| Almirall LLC | $75.88 | 2022-2023 | Seysara |
| Incyte Corporation | $52.44 | 2022-2023 | Opzelura |
| Galderma Laboratories, L.P. | $49.23 | 2021-2023 | Oracea, Aklief, Twyneo |
| Verrica Pharmaceuticals INC. | $44.87 | 2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $39.69 | 2022 | |
| Journey Medical Corporation | $38.45 | 2022-2023 | |
| Pfizer INC. | $38.32 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.03 | 2023 | Sotyktu |
| Amgen INC. | $20.48 | 2024 | Otezla |
| Paratek Pharmaceuticals, INC. | $19.42 | 2024 | Nuzyra |
| Helsinn Therapeutics (U.S.), INC. | $16.37 | 2023 | Valchlor |
| Irhythm Technologies, INC. | $16.15 | 2024 | Zio Xt Patch, Zio Monitor |
| Arcutis Biotherapeutics, INC. | $15.68 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chante Aksut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.